Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — Share-based compensation expense

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Innovate's life sciences — share-based compensation expense?
Innovate (VATE) reported life sciences — share-based compensation expense of $100K in Q1 2026.
How has Innovate's life sciences — share-based compensation expense changed year-over-year?
Innovate's life sciences — share-based compensation expense decreased by 66.7% year-over-year, from $300K to $100K.
What does life sciences — share-based compensation expense mean?
This metric measures the non-cash expense recognized by the Life Sciences segment related to equity-based awards granted to employees and management. It provides insight into the segment's talent retention strategy and the dilution impact on shareholders.